AT
IRD

Arden Trust’s Opus Genetics IRD Stock Holding History

Arden Trust’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-104
Closed -$13 – 516
2016
Q2 		$13 Hold
104
– – ﹤0.01% 639
2016
Q1 		$17K Buy
+104
New +$17.3K ﹤0.01% 625
2015
Q4 		– Sell
-104
Closed -$26K – 677
2015
Q3 		$26K Hold
104
– – ﹤0.01% 725
2015
Q2 		$33 Buy
+104
New +$35.3K ﹤0.01% 418

Other funds holding IRD

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HVIA
Hudson Valley Investment Advisors Goshen, New York $823M AUM 31.4% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Arden Trust's IRD Position: Q3 2016 in Review

Arden Trust sold out of Opus Genetics (IRD) in Q3 2016, closing a stake of 104 shares — an estimated $13 sold.

Arden Trust first reported a position in IRD in Q2 2015 and held it in 4 quarters. The position peaked at $26K in Q3 2015. 33 funds tracked by Wall St. Rank hold IRD as of Q3 2016.

  • Arden Trust reported no remaining Opus Genetics position as of Q3 2016 after selling out during the quarter.
  • Arden Trust sold 104 Opus Genetics shares in Q3 2016, an estimated $13.
  • Arden Trust first reported a position in Opus Genetics in Q2 2015 and held it in 4 quarters.
  • Arden Trust's Opus Genetics position peaked at $26K in Q3 2015.
  • 33 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2016.

Based on Arden Trust's 13F filing for Q3 2016, filed 14 Oct 2016.